193 related articles for article (PubMed ID: 37894922)
1. Histone Methyltransferases G9a/
Souza BK; Freire NH; Monteiro TS; Herlinger AL; Jaeger M; Dalmolin MGS; de Farias CB; Gregianin L; Brunetto AT; Brunetto AL; Thiele CJ; Roesler R
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894922
[TBL] [Abstract][Full Text] [Related]
2. Druggable epigenetic suppression of interferon-induced chemokine expression linked to
Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720
[TBL] [Abstract][Full Text] [Related]
3. De novo methylation of histone H3K23 by the methyltransferases EHMT1/GLP and EHMT2/G9a.
Vinson DA; Stephens KE; O'Meally RN; Bhat S; Dancy BCR; Cole RN; Yegnasubramanian S; Taverna SD
Epigenetics Chromatin; 2022 Nov; 15(1):36. PubMed ID: 36411491
[TBL] [Abstract][Full Text] [Related]
4. Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.
Lu Z; Tian Y; Salwen HR; Chlenski A; Godley LA; Raj JU; Yang Q
Anticancer Drugs; 2013 Jun; 24(5):484-93. PubMed ID: 23466651
[TBL] [Abstract][Full Text] [Related]
5. G9a/EHMT2 is a Potential Prognostic Biomarker and Molecular Target in SHH Medulloblastoma.
Souza BK; Freire NH; Jaeger M; de Farias CB; Brunetto AL; Brunetto AT; Roesler R
Neuromolecular Med; 2022 Dec; 24(4):392-398. PubMed ID: 35113321
[TBL] [Abstract][Full Text] [Related]
6. GLP overexpression is associated with poor prognosis in Chronic Lymphocytic Leukemia and its inhibition induces leukemic cell death.
Alves-Silva JC; de Carvalho JL; Rabello DA; Serejo TRT; Rego EM; Neves FAR; Lucena-Araujo AR; Pittella-Silva F; Saldanha-Araujo F
Invest New Drugs; 2018 Oct; 36(5):955-960. PubMed ID: 29855824
[TBL] [Abstract][Full Text] [Related]
7. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.
Watson ZL; Yamamoto TM; McMellen A; Kim H; Hughes CJ; Wheeler LJ; Post MD; Behbakht K; Bitler BG
Clin Epigenetics; 2019 Nov; 11(1):165. PubMed ID: 31775874
[TBL] [Abstract][Full Text] [Related]
8. The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer.
Mayr C; Helm K; Jakab M; Ritter M; Shrestha R; Makaju R; Wagner A; Pichler M; Beyreis M; Staettner S; Jaeger T; Klieser E; Kiesslich T; Neureiter D
Hum Pathol; 2018 Feb; 72():117-126. PubMed ID: 29133140
[TBL] [Abstract][Full Text] [Related]
9. Distinct roles for histone methyltransferases G9a and GLP in cancer germ-line antigen gene regulation in human cancer cells and murine embryonic stem cells.
Link PA; Gangisetty O; James SR; Woloszynska-Read A; Tachibana M; Shinkai Y; Karpf AR
Mol Cancer Res; 2009 Jun; 7(6):851-62. PubMed ID: 19531572
[TBL] [Abstract][Full Text] [Related]
10. EHMT2/G9a as an Epigenetic Target in Pediatric and Adult Brain Tumors.
Souza BK; Freire NH; Jaeger M; de Farias CB; Brunetto AL; Brunetto AT; Roesler R
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681949
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic priming by EHMT1/EHMT2 in acute lymphoblastic leukemia induces TP53 and TP73 overexpression and promotes cell death.
Silva-Carvalho AÉ; Alencar APD; Resende MR; da Costa DF; Nonino A; Neves FAR; Saldanha-Araujo F
Toxicol In Vitro; 2020 Dec; 69():104992. PubMed ID: 32889036
[TBL] [Abstract][Full Text] [Related]
12. A post-translational modification switch controls coactivator function of histone methyltransferases G9a and GLP.
Poulard C; Bittencourt D; Wu DY; Hu Y; Gerke DS; Stallcup MR
EMBO Rep; 2017 Aug; 18(8):1442-1459. PubMed ID: 28615290
[TBL] [Abstract][Full Text] [Related]
13. FIH Is an Oxygen Sensor in Ovarian Cancer for G9a/GLP-Driven Epigenetic Regulation of Metastasis-Related Genes.
Kang J; Shin SH; Yoon H; Huh J; Shin HW; Chun YS; Park JW
Cancer Res; 2018 Mar; 78(5):1184-1199. PubMed ID: 29259012
[TBL] [Abstract][Full Text] [Related]
14. The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia.
Pappano WN; Guo J; He Y; Ferguson D; Jagadeeswaran S; Osterling DJ; Gao W; Spence JK; Pliushchev M; Sweis RF; Buchanan FG; Michaelides MR; Shoemaker AR; Tse C; Chiang GG
PLoS One; 2015; 10(7):e0131716. PubMed ID: 26147105
[TBL] [Abstract][Full Text] [Related]
15. Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc-driven liver cancer.
Thng DKH; Hooi L; Toh CCM; Lim JJ; Rajagopalan D; Syariff IQC; Tan ZM; Rashid MBMA; Zhou L; Kow AWC; Bonney GK; Goh BKP; Kam JH; Jha S; Dan YY; Chow PKH; Toh TB; Chow EK
Mol Oncol; 2023 Nov; 17(11):2275-2294. PubMed ID: 36896891
[TBL] [Abstract][Full Text] [Related]
16. Expression and prognostic significance of chromatin modulators EHMT2/G9a and KDM2b in acute myeloid leukemia.
Gouda MBY; Zidane MA; Abdelhady AS; Hassan NM
J Cell Biochem; 2022 Aug; 123(8):1340-1355. PubMed ID: 35696556
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel histone lysine methyltransferase G9a/GLP (EHMT2/1) inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidines.
Katayama K; Ishii K; Tsuda E; Yotsumoto K; Hiramoto K; Suzuki M; Yasumatsu I; Igarashi W; Torihata M; Ishiyama T; Katagiri T
Bioorg Med Chem Lett; 2020 Oct; 30(20):127475. PubMed ID: 32781218
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic Silencing of 15-Hydroxyprostaglandin Dehydrogenase by Histone Methyltransferase EHMT2/G9a in Cholangiocarcinoma.
Zhang J; Chen W; Ma W; Song K; Lee S; Han C; Wu T
Mol Cancer Res; 2022 Mar; 20(3):350-360. PubMed ID: 34880125
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of EHMT2/G9a epigenetically increases the transcription of Beclin-1 via an increase in ROS and activation of NF-κB.
Park SE; Yi HJ; Suh N; Park YY; Koh JY; Jeong SY; Cho DH; Kim CS; Hwang JJ
Oncotarget; 2016 Jun; 7(26):39796-39808. PubMed ID: 27174920
[TBL] [Abstract][Full Text] [Related]
20. Selective histone methyltransferase G9a inhibition reduces metastatic development of Ewing sarcoma through the epigenetic regulation of NEU1.
García-Domínguez DJ; Hajji N; López-Alemany R; Sánchez-Molina S; Figuerola-Bou E; Morón Civanto FJ; Rello-Varona S; Andrés-León E; Benito A; Keun HC; Mora J; Tirado ÓM; de Álava E; Hontecillas-Prieto L
Oncogene; 2022 Apr; 41(18):2638-2650. PubMed ID: 35354905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
